By Megan Scudellari

Last month, the US Food and Drug Administration (FDA) sent letters to five commercial providers of direct-to-consumer genetic tests, stating that the companies’ devices must receive regulatory approval before they can be marketed. The move, which stops short of requiring the tests to be pulled from the market, may eventually increase consumer trust, but it could curtail current research. (Click here to continue reading)